Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

Mean lipid profile (mmol/L) upon completion of the experimental period. by Elsie D. Oduor (22521785)

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”

Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions. by Jiefeng Zhao (9090305)

Subjects:

Health inequalities in the burden of IBD among WCBA. by Jiefeng Zhao (9090305)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects: